Immatics to Post FY2024 Earnings of ($1.03) Per Share, Leerink Partnrs Forecasts (NASDAQ:IMTX)

Immatics (NASDAQ:IMTX) – Investment analysts at Leerink Partnrs decreased their FY2024 earnings per share (EPS) estimates for shares of Immatics in a report issued on Monday, September 16th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of ($1.03) for the year, down from their previous forecast of ($1.02). The consensus estimate for Immatics’ current full-year earnings is ($0.99) per share. Leerink Partnrs also issued estimates for Immatics’ FY2025 earnings at ($1.89) EPS.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.17. Immatics had a negative net margin of 103.99% and a negative return on equity of 23.34%. The firm had revenue of $20.19 million during the quarter, compared to the consensus estimate of $12.36 million.

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Immatics in a research note on Thursday, September 5th.

Immatics Trading Up 0.2 %

Shares of IMTX stock opened at $12.19 on Thursday. The stock has a market cap of $1.03 billion, a P/E ratio of -11.50 and a beta of 0.75. Immatics has a 1 year low of $7.15 and a 1 year high of $13.77. The stock has a 50 day simple moving average of $11.81 and a 200 day simple moving average of $11.57.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC increased its position in Immatics by 76.5% during the 2nd quarter. Perceptive Advisors LLC now owns 8,086,159 shares of the company’s stock worth $93,961,000 after purchasing an additional 3,503,750 shares in the last quarter. Vestal Point Capital LP acquired a new position in shares of Immatics during the fourth quarter worth $22,113,000. RA Capital Management L.P. bought a new position in shares of Immatics in the 1st quarter valued at $18,392,000. Goldman Sachs Group Inc. boosted its holdings in shares of Immatics by 324.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,548,909 shares of the company’s stock valued at $16,310,000 after acquiring an additional 1,183,860 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. acquired a new position in Immatics in the 2nd quarter worth about $13,392,000. Institutional investors own 64.41% of the company’s stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.